LLY

1,021.22

-2.93%↓

JNJ

243.76

+0.38%↑

ABBV

227

-2.16%↓

NVS

165.91

+0.18%↑

MRK

120.8

-0.53%↓

LLY

1,021.22

-2.93%↓

JNJ

243.76

+0.38%↑

ABBV

227

-2.16%↓

NVS

165.91

+0.18%↑

MRK

120.8

-0.53%↓

LLY

1,021.22

-2.93%↓

JNJ

243.76

+0.38%↑

ABBV

227

-2.16%↓

NVS

165.91

+0.18%↑

MRK

120.8

-0.53%↓

LLY

1,021.22

-2.93%↓

JNJ

243.76

+0.38%↑

ABBV

227

-2.16%↓

NVS

165.91

+0.18%↑

MRK

120.8

-0.53%↓

LLY

1,021.22

-2.93%↓

JNJ

243.76

+0.38%↑

ABBV

227

-2.16%↓

NVS

165.91

+0.18%↑

MRK

120.8

-0.53%↓

Search

Twist Bioscience Corp

Open

SectorHealthcare

56.74 12.87

Overview

Share price change

24h

Current

Min

50.72

Max

57.02

Key metrics

By Trading Economics

Income

-3.4M

-31M

Sales

4.7M

104M

Profit margin

-29.419

Employees

979

EBITDA

-3.2M

-24M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+5.88% upside

Dividends

By Dow Jones

Next Earnings

4 May 2026

Market Stats

By TradingEconomics

Market Cap

409M

3B

Previous open

43.87

Previous close

56.74

News Sentiment

By Acuity

50%

50%

165 / 351 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Twist Bioscience Corp Chart

Past performance is not a reliable indicator of future results.

Related News

17 Feb 2026, 23:44 UTC

Hot Stocks

Stocks to Watch: La-Z-Boy, Palo Alto Networks, Caesars

17 Feb 2026, 23:20 UTC

Earnings

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps -- Update

17 Feb 2026, 22:57 UTC

Earnings

Santos Fiscal Year Net Profit Falls 33%, Nears Start of Alaska Project

17 Feb 2026, 21:59 UTC

Earnings

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps

17 Feb 2026, 23:54 UTC

Market Talk

Nikkei May Rise as Fears About AI Disruption Ease -- Market Talk

17 Feb 2026, 23:54 UTC

Market Talk

Global Equities Roundup: Market Talk

17 Feb 2026, 23:54 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 Feb 2026, 23:45 UTC

Market Talk

Suncorp's Outperformance of IAG Could Be Hard to Sustain -- Market Talk

17 Feb 2026, 23:19 UTC

Earnings

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

17 Feb 2026, 23:15 UTC

Earnings

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

17 Feb 2026, 22:58 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Netflix Would Operate Warner's Studios, HBO Largely the Same -- Market Talk

17 Feb 2026, 22:58 UTC

Acquisitions, Mergers, Takeovers

BlueScope Steel: Board Committed to Optimizing Value For Shareholders

17 Feb 2026, 22:57 UTC

Acquisitions, Mergers, Takeovers

BlueScope Steel to Consider Revised SGH, Steel Dynamics Takeover Bid

17 Feb 2026, 22:50 UTC

Acquisitions, Mergers, Takeovers

Agnico-Eagle Mines Acquired 662,780 Common Shrs of Maple Gold Mines at C$2.45 Per Common Shr >AEM.T

17 Feb 2026, 22:44 UTC

Earnings

Palo Alto Reports Strong Earnings. Its Stock Is Down. -- Barrons.com

17 Feb 2026, 22:42 UTC

Earnings

Santos FY Net Profit Falls 33%, Nears Start of Alaska Project

17 Feb 2026, 22:36 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Netflix Sarandos: Paramount Causing Confusion Around Warner Deal -- Market Talk

17 Feb 2026, 22:36 UTC

Earnings

Santos Final Dividend 10.3 U.S. Cents/Security

17 Feb 2026, 22:36 UTC

Earnings

Santos FY Underlying Profit US$898 Million, Down 25%

17 Feb 2026, 22:35 UTC

Earnings

Santos FY Revenue US$4.94 Billion, Down 8%

17 Feb 2026, 22:35 UTC

Earnings

Correct: Santos FY Net Profit US$818 Million, Down 33%

17 Feb 2026, 22:35 UTC

Acquisitions, Mergers, Takeovers

Berkshire Buys New York Times Stock; Sells Apple, Bank of America, Amazon In 4Q -- Barrons.com

17 Feb 2026, 22:34 UTC

Earnings

Santos FY Net Profit US$818 Billion, Down 33%

17 Feb 2026, 22:02 UTC

Acquisitions, Mergers, Takeovers

Berkshire Pares Stakes in Apple and BofA, Adds New York Times Position -- Update

17 Feb 2026, 21:50 UTC

Acquisitions, Mergers, Takeovers

Steel Dynamics: SGH Would Buy BlueScope, On-sell North American Operations to SDI, As Earlier Proposed

17 Feb 2026, 21:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

17 Feb 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 Feb 2026, 21:49 UTC

Acquisitions, Mergers, Takeovers

Steel Dynamics Says Revised Proposal Continues to Present Highly Strategic Opportunity For SDI Shareholders

17 Feb 2026, 21:48 UTC

Acquisitions, Mergers, Takeovers

Steel Dynamics: BlueScope Offer a 56% Premium to 52-Week Volume Weighted Average Price

17 Feb 2026, 21:48 UTC

Acquisitions, Mergers, Takeovers

Steel Dynamics: Consideration To Be Comprised Entirely of Cash

Peer Comparison

Price change

Twist Bioscience Corp Forecast

Price Target

By TipRanks

5.88% upside

12 Months Forecast

Average 52 USD  5.88%

High 58 USD

Low 50 USD

Based on 6 Wall Street analysts offering 12 month price targets forTwist Bioscience Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

31.56 / 38.6884Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

165 / 351 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat